المؤلفون: Haydu JE; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Maron JS; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA., Redd RA; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA., Gallagher KME; Immune Monitoring Laboratory, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA; and., Fischinger S; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA., Barnes JA; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Hochberg EP; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Johnson PC; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Takvorian RW; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Katsis K; Immune Monitoring Laboratory, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA; and., Portman D; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Ruiters J; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Sechio S; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Devlin M; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Regan C; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Blumenthal KG; Department of Allergy and Immunology., Banerji A; Department of Allergy and Immunology., Judd AD; Department of Allergy and Immunology., Scorsune KJ; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., McGree BM; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Sherburne MM; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Lynch JM; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Weitzman JI; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Lei M; Department of Pharmacy., Kotton CN; Department of Infectious Diseases, and., Dighe AS; Department of Pathology, Massachusetts General Hospital, Boston, MA., Maus MV; Immune Monitoring Laboratory, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA; and., Alter G; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA., Abramson JS; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Soumerai JD; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA.

المصدر: Blood advances [Blood Adv] 2022 Mar 22; Vol. 6 (6), pp. 1671-1683.

نوع المنشور: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19*/prevention & control , Leukemia, Lymphocytic, Chronic, B-Cell*/therapy, Adult ; Antibodies, Neutralizing ; COVID-19 Vaccines ; Humans ; Immunogenicity, Vaccine ; Prospective Studies ; SARS-CoV-2